Our science is visionary.
Our commitment is relentless.
preserve vision and
Qlaris Bio is a clinical stage biotechnology company founded on a relentless commitment to develop innovative first-in-class therapies that can make a truly impactful change for patients suffering from serious and debilitating ophthalmic diseases.
We are exploring novel mechanisms of action to address the largest unmet needs in ophthalmology.
Our lead asset, QLS-101, has a unique vasodilatory mechanism of action and is designed to lower intraocular pressure (IOP) by reducing episcleral venous pressure (EVP) and distal outflow resistance beyond the trabecular meshwork. By reducing EVP and distal outflow resistance, QLS-101 has the potential to enable the achievement of lower IOP targets than available therapies currently allow.
QLS-101 is currently in clinical trials for the treatment of Primary Open Angle Glaucoma, Ocular Hypertension, Normal Tension Glaucoma, and Sturge-Weber syndrome.
Our early pipeline includes QLS-700, a platform for a truly groundbreaking first-in-class targeted gene-based therapeutic that we are evaluating for the treatment of glaucoma.
Recent News See All News
Qlaris Bio Named 2022 Scrip Awards Finalist for Biotech Company of the Year
Annual awards program recognizes innovations and achievements in global biopharma Wellesley, Mass., September 28, 2022 – Qlaris Bio, Inc, a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today it has been named a finalist in the WuXi AppTec’s Biotech Company of the Year category of the 2022 Scrip Awards. Qlaris has seen […]
Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101
Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101 Findings from First-in-Human Study Support Continued Clinical Development of Investigational IOP-lowering Therapy; New Trials Planned as Complementary Glaucoma Treatment and in Rare Pediatric Indication Wellesley, Mass., May 18, 2022 – Qlaris Bio, Inc. (the “Company” or “Qlaris”), […]